{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:57Z","timestamp":1753891857457,"version":"3.41.2"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Classification of patients with chronic lymphocytic leukemia (CLL) based on the somatic hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable (IGHV) gene has established predictive and prognostic relevance. The SHM status is assessed based on the number of mutations within the IG heavy variable domain sequence, albeit only over the rearranged IGHV gene excluding the variable heavy complementarity determining region 3 (VH CDR3). This may lead to an underestimation of the actual impact of SHM, in fact overlooking the most critical region for antigen-antibody interactions, i.e. the VH CDR3. Here we investigated whether SHM may be present within the VH CDR3 of cases bearing \u2018truly unmutated\u2019 IGHV genes (i.e. 100% germline identity across VH FR1-VH FR3) employing Next Generation Sequencing. We studied 16 patients bearing a \u2018truly unmutated\u2019 CLL clone assigned to stereotyped subsets #1 (n=12) and #6 (n=4). We report the existence of SHM within the germline-encoded 3\u2019IGHV, IGHD, 5\u2019IGHJ regions of the VH CDR3 in both the main IGHV-IGHD-IGHJ gene clonotype and its variants. Recurrent somatic mutations were identified between different patients of the same subset, supporting the notion that they represent true mutational events rather than technical artefacts; moreover, they were located adjacent to\/within AID hotspots, pointing to SHM as the underlying mechanism. In conclusion, we provide immunogenetic evidence for intra-VH CDR3 variations, attributed to SHM, in CLL patients carrying \u2018truly unmutated\u2019 IGHV genes. Although the clinical implications of this observation remain to be defined, our findings offer a new perspective into the immunobiology of CLL, alluding to the operation of VH CDR3-restricted SHM in U-CLL.<\/jats:p>","DOI":"10.3389\/fonc.2022.1079772","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T08:38:07Z","timestamp":1671007087000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Evidence of somatic hypermutation in the antigen binding sites of patients with CLL harboring IGHV genes with 100% germline identity"],"prefix":"10.3389","volume":"12","author":[{"given":"Electra","family":"Sofou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Zaragoza-Infante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Pechlivanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Karakatsoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Notopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niki","family":"Stavroyianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fotis","family":"Psomopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisavet","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Langlois","family":"de Septenville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Davi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Agathangelidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Chatzidimitriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostas","family":"Stamatopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3009","article-title":"Chronic lymphocytic leukemia b cells express restricted sets of mutated and unmutated antigen receptors","volume":"102","author":"Fais","year":"1998","journal-title":"J Clin Invest"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.clml.2019.03.002","article-title":"Prognostic and predictive effect of IGHV mutational status and load in chronic lymphocytic leukemia: Focus on FCR and BR treatments","volume":"19","author":"Visentin","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1479-5876-10-18","article-title":"IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia","volume":"10","author":"Bulian","year":"2012","journal-title":"J Transl Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184853","article-title":"Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens","volume":"113","author":"Lin","year":"2009","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.195032","article-title":"Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia","volume":"104","author":"Baliakas","year":"2019","journal-title":"Haematologica"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.leu.2404457","article-title":"ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia","volume":"21","author":"Ghia","year":"2007","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.125","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations","volume":"31","author":"Rosenquist","year":"2017","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01604-2","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European research initiative on CLL","volume":"36","author":"Agathangelidis","year":"2022","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-393694","article-title":"Stereotyped b-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies","volume":"119","author":"Agathangelidis","year":"2012","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-1944-5_16","article-title":"Exploring the diversity of the b-cell receptor repertoire through high-throughput sequencing","volume":"2421","author":"Hom","year":"2022","journal-title":"Methods Mol Biol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.307","article-title":"Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia","volume":"31","author":"Stamatopoulos","year":"2017","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2164","article-title":"Structural and functional features of the b-cell receptor in IgG-positive chronic lymphocytic leukemia","volume":"12","author":"Potter","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-1-4939-8876-1_5","article-title":"Immunoglobulin gene analysis in chronic lymphocytic leukemia","volume":"1881","author":"Agathangelidis","year":"2019","journal-title":"Methods Mol Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s12859-020-03669-1","article-title":"TRIP - T cell receptor\/immunoglobulin profiler","volume":"21","author":"Kotouza","year":"2020","journal-title":"BMC Bioinf"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00851","article-title":"Standardization of sequencing coverage depth in NGS: Recommendation for detection of clonal and subclonal mutations in cancer diagnostics","volume":"9","author":"Petrackova","year":"2019","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.1777.1777","article-title":"Distinct profiles of in vivo class switch recombination in chronic lymphocytic leukemia subsets with stereotyped b cell receptors, suggestive of distinct modes of activation by antigen","volume":"120","author":"Xochelli","year":"2012","journal-title":"Blood"},{"key":"B20","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020007039","article-title":"Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL","volume":"137","author":"Agathangelidis","year":"2021","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2006-03-012948","article-title":"Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations","volume":"109","author":"Stamatopoulos","year":"2007","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)00005-2","article-title":"Clinical effect of stereotyped b-cell receptor immunoglobulins in chronic lymphocytic leukaemia: A retrospective multicentre study","volume":"1","author":"Baliakas","year":"2014","journal-title":"Lancet Haematol"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2004-01-0132","article-title":"Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia","volume":"104","author":"Tobin","year":"2004","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2007-07-099564","article-title":"Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: Implications for the role of antigen selection in leukemogenesis","volume":"111","author":"Murray","year":"2008","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0630","article-title":"Immunogenetic studies of chronic lymphocytic leukemia: Revelations and speculations about ontogeny and clinical evolution","volume":"74","author":"Vardi","year":"2014","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20120833","article-title":"Cellular origin and pathophysiology of chronic lymphocytic leukemia","volume":"209","author":"Seifert","year":"2012","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-155663","article-title":"Cellular origin(s) of chronic lymphocytic leukemia: Cautionary notes and additional considerations and possibilities","volume":"117","author":"Chiorazzi","year":"2011","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.322","article-title":"Antigen receptor stereotypy in chronic lymphocytic leukemia","volume":"31","author":"Stamatopoulos","year":"2017","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.10.009","article-title":"High-throughput immunogenetics for precision medicine in cancer","volume":"84","author":"Agathangelidis","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005216","article-title":"Higher order immunoglobulin repertoire restrictions in cll: the illustrative case of stereotyped subsets 2 and 169","volume":"137","author":"Gemenetzi","year":"2020","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.640731","article-title":"Post-transformation IGHV-IGHD-IGHJ mutations in chronic lymphocytic leukemia b cells: Implications for mutational mechanisms and impact on clinical course","volume":"11","author":"Bagnara","year":"2021","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-221309","article-title":"Extensive intraclonal diversification in a subgroup of chronic lymphocytic leukemia patients with stereotyped IGHV4-34 receptors: implications for ongoing interactions with antigen","volume":"114","author":"Sutton","year":"2009","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.semcancer.2015.04.009","article-title":"The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia","volume":"34","author":"Sutton","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4161\/epi.22901","article-title":"Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles","volume":"7","author":"Kanduri","year":"2012","journal-title":"Epigenetics"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2011.00480","article-title":"Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors","volume":"18","author":"Ntoufa","year":"2012","journal-title":"Mol Med"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00788","article-title":"AID overlapping and pol\u03b7 hotspots are key features of evolutionary variation within the human antibody heavy chain (IGHV) genes","volume":"11","author":"Tang","year":"2020","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0167602","article-title":"The number of overlapping AID hotspots in germline IGHV genes is inversely correlated with mutation frequency in chronic lymphocytic leukemia","volume":"12","author":"Yuan","year":"2017","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.634383","article-title":"AID in chronic lymphocytic leukemia: Induction and action during disease progression","volume":"11","author":"Oppezzo","year":"2021","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1079772\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T08:38:15Z","timestamp":1671007095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1079772\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":39,"alternative-id":["10.3389\/fonc.2022.1079772"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1079772","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"article-number":"1079772"}}